Boland, Michelle L.
AstraZeneca (United States)
3 papers on CoChat
Most cited papers
- Verified
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Boland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 270
- Verified
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
Boland, M. L., Oró, D., Tølbøl, K. S., Thrane, S. T., Nielsen, J. C., Cohen, T. S., Tabor, D. E., Fernandes, F., Tovchigrechko, A., Veidal, S. S., et al. (2019) · World Journal of Gastroenterology
Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease
Cited by 129
- Verified
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 59
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free